Buying Buzz: NexImmune Inc. [NEXI] Director Verstandig Grant acquires 26,876 shares of the company

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NexImmune Inc. shares valued at $61,385 were purchased by Verstandig Grant on Jun 07. At $2.28 per share, Verstandig Grant acquired 26,876 shares. The insider’s holdings grew to 1,105,495 shares worth approximately $0.71 million following the completion of this transaction.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Also, Verstandig Grant purchased 25,000 shares, netting a total of over 53,538 in proceeds. Following the buying of shares at $2.14 each, the insider now holds 1,078,619 shares.

Before that, Verstandig Grant had added 15,000 shares to its account. In a trade valued at $33,374, the Director bought NexImmune Inc. shares for $2.22 each. Upon closing the transaction, the insider’s holdings increased to 15,000 shares, worth approximately $0.67 million.

As published in their initiating research note from Raymond James on April 01, 2021, NexImmune Inc. [NEXI] has been an Outperform and the price target has been revised to $30. This represents a 97.87% premium over Thursday’s closing price. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of March 09, 2021, Barclays has initiated its “an Overweight” rating for NEXI.

Analyzing NEXI’s Price Performance

On Thursday, NexImmune Inc. [NASDAQ: NEXI] rose 7.85% to $0.64. The stock’s lowest price that day was $0.58, but it reached a high of $0.6899 in the same session. During the last five days, there has been a drop of approximately -18.23%. Over the course of the year, NexImmune Inc. shares have dropped approximately -86.08%. Shares of the company reached a 52-week high of $4.9100 on 03/28/22 and a 52-week low of $0.5703 on 09/21/22. A 50-day SMA is recorded $1.1643, while a 200-day SMA reached $2.4995. Nevertheless, trading volume fell to 1.08 million shares from 0.27 million shares the previous day.

Support And Resistance Levels for NexImmune Inc. (NEXI)

According to the 24-hour chart, there is a support level at 0.5846, which, if violated, would cause prices to drop to 0.5273. In the upper region, resistance lies at 0.6945. The next price resistance is at 0.7471. RSI (Relative Strength Index) is 27.21 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.2630, which suggests the price will decrease in the coming days. Percent R is at 92.99%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is NexImmune Inc. subject to short interest?

Stocks of NexImmune Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.54 million shares to 0.46 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 1.0 million shares. A decline of -119.49% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.15 of the overall float, the days-to-cover ratio (short ratio) decline to 0.15.

Which companies own the most shares of NexImmune Inc. (NEXI)?

According to ArrowMark Colorado Holdings LLC filings, the company currently owns 1,326,043 shares, which is about 5.49% of the total NEXI shares outstanding. In its current portfolio, The Vanguard Group, Inc. holds 444,644 shares valued at $0.52 million.

In terms of NexImmune Inc. share price expectations, FactSet research, analysts set an average price target of $3.50 in the next 12 months, up nearly 483.33% from the previous closing price of $0.60. Analysts anticipate NexImmune Inc. stock to reach $5.00 by 2022, with the lowest price target being $2.00. In spite of this, 4 analysts ranked NexImmune Inc. stock as an Overweight at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here